BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/11/2014 8:39:00 PM | Browse: 1032 | Download: 803
Publication Name World Journal of Gastroenterology
Manuscript ID 5321
Country/Territory Greece
Received
2013-08-29 09:27
Peer-Review Started
2013-08-29 16:47
To Make the First Decision
2013-09-27 16:46
Return for Revision
2013-09-29 14:31
Revised
2013-10-25 07:08
Second Decision
2013-11-01 16:58
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2013-11-03 11:41
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2013-12-12 15:03
Publish the Manuscript Online
2014-01-20 16:41
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Topic Highlights
Article Title Hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy
Manuscript Source Invited Manuscript
All Author List John Vlachogiannakos and George Papatheodoridis
Funding Agency and Grant Number
Corresponding Author George Papatheodoridis, MD, Academic Department of Gastroenterology, Athens University Medical School, Laiko General Hospital, Agiou Thoma 17, 11527 Athens, Greece. gepapath@med.uoa.gr
Key Words Chronic hepatitis B; Hepatocellular carcinoma; Interferon; Lamivudine; Adefovir; Entecavir; Tenofovir; Virological remission; Cirrhosis
Core Tip Antiviral therapy reduces but does not eliminate the risk of hepatocellular carcinoma (HCC) in chronic hepatitis B patients with or without cirrhosis. The reduction of the HCC incidence under a high genetic barrier nucleos(t)ide analogue is higher in the vast majority of patients who will achieve virological remission compared to those who may maintain detectable viral replication. In current clinical practice, however, patients at increased baseline HCC risk should continue to undergo HCC surveillance according to the existing recommendations even if they have achieved complete long-term inhibition of viral replication and improvements in liver histology.
Publish Date 2014-01-20 16:41
Citation Vlachogiannakos J, Papatheodoridis G. Hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy. World J Gastroenterol 2013; 19(47): 8822-8830
URL http://www.wjgnet.com/1007-9327/full/v19/i47/8822.htm
DOI http://dx.doi.org/10.3748/wjg.v19.i47.8822
Full Article (PDF) WJG-19-8822.pdf
Manuscript File 5321-Review.doc
Answering Reviewers 5321-Answering Reviewers.pdf
Copyright License Agreement 5321-Copyright Assignment.pdf
Peer-review Report 5321-Peer Review(s).pdf
Scientific Editor Work List 5321-Scientific editor work list.doc